Compare Incyte Corporation (INCY) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Rocket Lab USA Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Rocket Lab USA Inc trades at $67.12 (market cap $41.08B). The key difference: Rocket Lab USA Inc is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals.
| INCY | RKLB | |
|---|---|---|
Market Cap | $23.11B | $41.08B |
Sector | Health | Technology |
52-Week High | $118.52 | $150.23 |
52-Week Low | $67.38 | $39.48 |
Enterprise Value | $19.13B | $39.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Rocket Lab (RKLB) trades at $65.74, down 2.78% on the day, reflecting a bearish technical trend with support at $63. The company shows strong revenue growth with $601.80M in 2025 but remains unprofitable with a net loss of $198.21M. Recent news highlights competition with SpaceX and a potential catalyst from the Neutron rocket's development. Analyst consensus is overwhelmingly bullish with a $116.90 price target, though technical indicators signal near-term caution.
The outlook for RKLB hinges on execution of its growth strategy and path to profitability. Investment opportunity lies in its expanding launch contracts and competitive positioning in the space sector. Key risks include persistent cash burn, intense competition, and reliance on successful Neutron launches. Investors should weigh strong analyst optimism against fundamental challenges and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
